Table 4. Complete remission rates,... | American Society of Hematology

Table 4.

Complete remission rates, reasons for failure, relapse risk, and survival in Medical Research Council trial AML11 by the new hierarchical cytogenetic risk group

Cytogenetic risk group^4-150	Total no.	CR and reason for failure			Relapse risk at 5 years, % (SE)	Overall survival
Cytogenetic risk group^4-150	Total no.	CR rate, %	Induction deaths, %	Resistant disease, %	Relapse risk at 5 years, % (SE)	At 5 years, % (SE)	Median
Favorable	78	72^4-151	21	8^4-151	56 (7.5)^4-151	34 (5.7)^4-151	559 days^4-151
Intermediate	842	59	18	23	81 (1.9)	13 (1.2)	276 days
Adverse	145	26	19	56	91 (5.1)	2 (1.2)	113 days

Cytogenetic risk group^4-150	Total no.	CR and reason for failure			Relapse risk at 5 years, % (SE)	Overall survival
Cytogenetic risk group^4-150	Total no.	CR rate, %	Induction deaths, %	Resistant disease, %	Relapse risk at 5 years, % (SE)	At 5 years, % (SE)	Median
Favorable	78	72^4-151	21	8^4-151	56 (7.5)^4-151	34 (5.7)^4-151	559 days^4-151
Intermediate	842	59	18	23	81 (1.9)	13 (1.2)	276 days
Adverse	145	26	19	56	91 (5.1)	2 (1.2)	113 days

P values are for Mantel-Haenszel (CR and reasons for failure) or log-rank (relapse risk and overall survival) test for trend. All P values remain at a similar level of significance when adjusted for age, type of leukemia (de novo or secondary), and white blood count at presentation.

CR indicates complete remission.

F4-150

Favorable: t(15;17), t(8;21), or inv(16) whether alone or in conjunction with other abnormalities. Intermediate: normal karyotype, all other noncomplex abnormalities. Adverse: complex karyotype (5 or more unrelated abnormalities), excluding cases with t(15;17), t(8;21), and inv(16).

F4-151

P < .001.

View Large

This Feature Is Available To Subscribers Only